Central Bank & Trust’s ImmunityBio IBRX Stock Holding History

Central Bank & Trust’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-80	Closed	-$505	–	265
2024 Q2	$505	Hold	80	–	–	﹤0.01%	357
2024 Q1	$429	Hold	80	–	–	﹤0.01%	333
2023 Q4	$400	Hold	80	–	–	﹤0.01%	350
2023 Q3	$135	Hold	80	–	–	﹤0.01%	333
2023 Q2	$221	Hold	80	–	–	﹤0.01%	323
2023 Q1	$144	Hold	80	–	–	﹤0.01%	422
2022 Q4	$405	Hold	80	–	–	﹤0.01%	334
2022 Q3	$0	Hold	80	–	–	﹤0.01%	323
2022 Q2	$0	Buy	+80	New	+$321	﹤0.01%	321

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Central Bank & Trust's IBRX Position: Q3 2024 in Review

Central Bank & Trust sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 80 shares — an estimated $505 sold.

Central Bank & Trust first reported a position in IBRX in Q2 2022 and held it in 9 quarters. The position peaked at $505 in Q2 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

Central Bank & Trust reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
Central Bank & Trust sold 80 ImmunityBio shares in Q3 2024, an estimated $505.
Central Bank & Trust first reported a position in ImmunityBio in Q2 2022 and held it in 9 quarters.
Central Bank & Trust's ImmunityBio position peaked at $505 in Q2 2024.
181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Central Bank & Trust's 13F filing for Q3 2024, filed 30 Oct 2024.